Orlistat, Sibutramine, or Combination Therapy : Which Performs Better on Waist Circumference in Relation with Body Mass Index in Obese Patients?

この論文にアクセスする

この論文をさがす

著者

    • AYDIN NESLIHAN
    • Department of Internal Medicine, Haydarpasa Numune Teaching and Research Hospital
    • TOPSEVER PINAR
    • Department of Family Medicine, Kocaeli University Faculty of Medicine
    • KAYA AYCA
    • Department of Internal Medicine, Haydarpasa Numune Teaching and Research Hospital
    • KARASAKAL MUZEYYEN
    • Department of Internal Medicine, Haydarpasa Numune Teaching and Research Hospital
    • DUMAN CELAL
    • Department of Internal Medicine, Haydarpasa Numune Teaching and Research Hospital
    • DAGAR ARSLAN
    • Department of Internal Medicine, Haydarpasa Numune Teaching and Research Hospital

抄録

The aim of this study was to evaluate decrease in waist circumference in obese patients receiving different anti-obesity treatments. The study was designed as a short-term (12 weeks), open-label, and randomized trial. Eighty six patients (70 females, 81.4%; mean age 41.09±8.73 years, mean BMI 36.1±4.3 kg/m<sup>2</sup>) were randomized to four different therapy groups. The primary outcome parameters were waist circumference and body mass index (BMI). The therapy groups were a) diet+sibutramine 1×10 mg/d (<i>n</i>=22), b) diet+orlistat 3×120 mg/d (<i>n</i>=25), c) combination of diet+sibutramine+orlistat (<i>n</i>=20) and d) diet (<i>n</i>=19). Combination therapy was more effective than diet and orlistat mono-therapy (<i>p</i><0.0001 for all), but not significantly superior to sibutramine mono-therapy (<i>p</i>=0.072) in decreasing BMI. Sibutramine mono-therapy was significantly more effective in inducing BMI decrease compared with orlistat mono-therapy (<i>p</i>=0.039). The association between change in BMI and change in waist circumference was strongest in the orlistat mono-therapy group (<i>P</i> interaction=0.003). This means that patients taking orlistat experienced more decrease in waist circumference (3.4 cm, <i>R</i><sup>2</sup>=0.29) per unit decrease in BMI compared to patients under combination therapy (2.6 cm, <i>R</i><sup>2</sup>=0.25, <i>P</i> interaction = 0.015) and patients taking sibutramine (1.8 cm, <i>R</i><sup>2</sup>=0.19, <i>P</i> interaction=0.026). In the diet therapy group decline in waist circumference was independent of BMI (1.9 cm, <i>R</i><sup>2</sup>=0.02, <i>P</i> interaction=0.076). Although combination therapy and sibutramine mono-therapy were more effective in decreasing BMI, reduction in waist circumference and BMI was most significantly associated with the orlistat mono-therapy group. This may hint at the possibility of orlistat inducing weight loss mainly in the abdominal area targeted to reduce cardiovascular risk.

収録刊行物

  • THE TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

    THE TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE 202(3), 173-180, 2004-03-01

    Tohoku University Medical Press

参考文献:  32件中 1-32件 を表示

被引用文献:  1件中 1-1件 を表示

各種コード

  • NII論文ID(NAID)
    10012709257
  • NII書誌ID(NCID)
    AA00863920
  • 本文言語コード
    ENG
  • 資料種別
    ART
  • ISSN
    00408727
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ